Last reviewed · How we verify

NCT03951714: ADVICE

Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence

Completed NA Last updated 1 July 2021
What this trial tests

NA trial testing Marketed experience application on adherence in Asthma in 160 participants. Completed in 6 July 2020.

Timeline
12 August 2019
Primary endpoint
6 July 2020
6 July 2020

Quick facts

Lead sponsorChiesi Farmaceutici S.p.A.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposesupportive care
Enrollment160
Start date12 August 2019
Primary completion6 July 2020
Estimated completion6 July 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Chiesi Farmaceutici S.p.A. — full company profile →

Who can join

18 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this Study is to assess the effect of a smartphone application connected to an add-on device system fitted on Pressured Metered Dose Inhaler (PMDI) on adherence to take medications as prescribed and clinical outcomes in difficult-to-treat asthmatic patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Digital interventions to improve adherence to maintenance medication in asthma.
    Chan A, De Simoni A, Wileman V, Holliday L, et al · · 2022 · cited 59× · PMID 35691614 · DOI 10.1002/14651858.cd013030.pub2

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Chiesi Farmaceutici S.p.A. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing